Evidence map›Paper›PMID 27632140›Full record

ArticleJournal of thrombosis and thrombolysis2017

Direct oral anticoagulants in hypercoagulable states.

Paul R Kunk, Jacqueline Brown, Melissa McShane, Surabhi Palkimas, B Gail Macik

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Drug-associated thrombocytopenia.Hematology. American Society of Hematology. Education Program · 2018
    Review
  10. Article
  11. Emerging Role of Direct Oral Anticoagulants in the Management of Heparin-Induced Thrombocytopenia.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Paul R KunkDivision of Hematology-Oncology, Department of Medicine, University of Virginia Health System, PO Box 800716, Charlottesville, VA, 22908-0716, USA. Prk5r@virginia.edu.
Jacqueline BrownDivision of Hematology-Oncology, Department of Medicine, University of Virginia Health System, PO Box 800716, Charlottesville, VA, 22908-0716, USA.
Melissa McShaneDivision of Hematology-Oncology, Department of Medicine, University of Virginia Health System, PO Box 800716, Charlottesville, VA, 22908-0716, USA.
Surabhi PalkimasDivision of Hematology, Department of Clinical Pharmacy, University of Virginia Health System, Charlottesville, VA, USA.
B Gail MacikDivision of Hematology-Oncology, Department of Medicine, University of Virginia Health System, PO Box 800716, Charlottesville, VA, 22908-0716, USA.
University of Virginia Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct oral anticoagulants have been shown safe and effective in the treatment of pulmonary emboli and deep vein thrombi. Their role in the treatment of patients with hypercoagulability is uncertain. We designed a retrospective exploratory analysis of all patients with definite heparin induced thrombocytopenia (HIT) and antiphospholipid syndrome (APS) that were treated with either apixaban or rivaroxaban from September 2011 through November 2015. Patients were reviewed for several clinico-pathologic features, including efficacy and safety. 23 patients were identified (12 patients with HIT and 11 patients with APS). Sixteen patients (70 %) were treated with apixaban and seven patients (30 %) were treated with rivaroxaban over a median follow up of 7 months (range 2-39). Zero patients developed recurrent thrombi. Two patients being treated for HIT developed major bleeding leading to discontinuation of all anticoagulation. Therefore, apixaban and rivaroxaban appear safe and effective for treatment of patients with HIT and APS in this small retrospective cohort and should be considered on an individual basis for patients who refuse, fail or are intolerant of warfarin. There were no sources of funding.

Indexed as

AdultAgedAnticoagulantsAntiphospholipid SyndromeFemaleHemorrhageHeparinHumansMaleMiddle AgedPyrazolesPyridonesRecurrenceRetrospective StudiesRivaroxabanThrombophiliaAnticoagulantsapixabanHeparinPyrazolesPyridonesRivaroxabanAntiphospholipid syndromeApixabanDirect oral anticoagulantHeparin induced thrombocytopeniaRivoraxaban

Identifiers

PMID27632140
OpenAlexW2513043212

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.